NewzIn the Dominican Republic, innovative medications for the treatment of obesity and diabetes remain inaccessible to patients through health insurance providers (ARS). Although these drugs were officially added to the national Basic Medication List over a year ago, the administrative and financial mechanisms required to provide coverage have not yet been implemented.
The delay in coverage leaves patients without the intended benefits of the updated national formulary. Despite the regulatory inclusion of these treatments, the lack of effective integration into the insurance system prevents individuals from obtaining the necessary financial support for these therapies.
In-depth summary · AI, neutral